Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. and among six selected hospitals of diverse size and from different geographic regions. We found 97.9% of reported LP tumor cases to fulfill current diagnostic criteria for having an LP tumor and observed 89.7% to have accurate LP tumor subtype. The overall completeness of non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma cases in the Cancer registry was 95-99% but was lower for the more indolent tumors, chronic lymphocytic leukemia (87.9 %) and Waldenström´s macroglobulinemia (68.1 %). We observed increased overall under-ascertainment for patients diagnosed above age 80 (27%) and among individuals diagnosed before 1973 (12%). In conclusion the diagnostic accuracy and completeness for classically defined LP tumor entities in the Swedish Cancer registry is high.
However, we found under-ascertainment of patients with indolent LP tumors, particularly among patients diagnosed at older ages, with early-stage disease, and diagnosed in earlier years.
INTRODUCTION
Population-based cancer registries provide key information about cancer incidence for specific cancers according to subtype, and histopathology, patterns of survival, and other aspects related to cancer treatment. Information about the patterns of specific cancers by age and gender is crucial for the design of clinical trials, for health care planning needs, and for potential clues about etiology and determinants of progression. Some studies examining population-based cancer registries have indicated systematic problems in the completeness of reporting within certain population subgroups, such as older patients, or for patients whose malignancies are characterized by more indolent features [1] [2] [3] [4] . For hematopoietic lymphoproliferative (LP) malignancies, there are only limited, if any, data available on potential variation in the accuracy and completeness of LP cancer diagnoses overall and within specific subgroups.
Since the mid-1950s Sweden has provided universal medical health care available for the entire population, currently approximately 9 million people. All physicians and pathologists are obliged by law to report incident cancer cases to the central population-based Swedish
Cancer registry which was established in 1958 1 . Due to its large size and unique features including digital record-linkage with other unique central databases with nationwide coverage (e.g., Multigenerational, Inpatient, Twin and Causes of Death registries), the Swedish Cancer registry has been widely used to study associations between personal or family history of certain defined diseases and subsequent risk of cancer, with the aim to provide etiologic and pathogenetic clues [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Also, by linking the Swedish Cancer registry to hospital-based routine diagnostic and treatment databases across the country, important large population-based studies have been conducted to examine risks of second malignancies among cancer survivors, and quantify second cancer risks in relation to radiation therapy, specific chemotherapy agents, combined modality treatments and combinations of other known better definitions of distinct LP tumor entities and to the development of more precise tools to achieve greater diagnostic accuracy 23 .
PATIENTS AND METHODS
As described in detail below, two study populations of LP tumor patients were evaluated in this investigation; one was recruited from the Swedish Inpatient registry (hospital-based In the beginning of the study period, the LP cases were classified using the Kiel diagnostic classification which was utilized by most hematopathologists in Sweden 24 . In the mid-1990s, it was replaced by the more developed REAL classification 25 , which evolved into the current WHO classification. The WHO classification was described in 2001 23 and applied subsequently. The hospital-based and the registry-based study populations were defined as described below.
Source and selection of the hospital-based study population
The Swedish Inpatient registry has been in operation since 1964 and contains nationwide information on discharge diagnoses and discharge listings from inpatient care 26 . During the January 1, 1964 to December 31, 2003 study period, all hematology/oncology clinics were centralized to 10 regional University hospitals, which offer inpatient hospital care to a defined primary catchment area population (typically 100,000 to 150,000 inhabitants) in addition to being the referral center for a whole health care region. The remaining hospitals in the country serve regions with 30,000 to 100,000 inhabitants and offer inpatient hospital care.
We charged the National Board of Health and Welfare to apply a computerized algorithm to select a stratified random sample of cases from Swedish Inpatient registry. A total of eight patients diagnosed with NHL and four patients each with HL, CLL, MM, and WM who were newly diagnosed with these malignancies in each of the four periods at each study hospital Table 2 ). Using this strategy, a total of 595 patients were selected from all study hospitals.
Source and selection of the registry-based study population
Information on every incident patient diagnosed with a malignant disorder in Sweden has to be reported to the centralized, nationwide Swedish Cancer registry which has been in operation since January 1, 1958 1, 7 . In the present study we limited the selection of LP case subjects to those diagnosed after January 1, 1964, because information on hospitalization discharge visits is not available in the Swedish Inpatient registry prior to that date 26 . Thus, we wanted the hospital-based and the registry-based study populations (see below) to cover the same study period. Every physician and pathologist/cytologist is obliged by law to report each case of cancer to the registry. For each LP case, the Swedish Cancer registry contains information on histopathological diagnosis, sex, date of birth, date at diagnosis, and hospital where the diagnosis was made. Each individual in Sweden receives a unique personal identification number and every death along with the date of death is recorded and centralized in the Causes of Death Register.
Similar to the approach we used for selecting the hospital-based study population, we requested the National Board of Health and Welfare to apply a computerized algorithm to select a stratified random sample of LP cases from Swedish Cancer registry. A total of eight patients diagnosed with NHL and four patients with HL, CLL, and MM, respectively, were identified during each of the four calendar-year periods at each hospital (Table 2) . Because WM is a very rare disease and since the majority of WM cases have been coded as "NHL unspecified" in the Swedish Cancer registry for most of the study years, we decided not to include WM cases in the registry-based study population.
Clinical data collection and outcome measures examined in both study populations
We retrieved available patient records and underlying relevant documentation for all patients in both study populations. For each patient, we reviewed medical records, laboratory results, and underlying relevant clinical documentation. All pathology reports at primary diagnosis were reviewed by one of us (IT). The date of diagnosis was captured from pathology reports, and if the date was missing (<10%) we used the diagnosis date given in the medical record. We assessed the given LP tumor diagnosis in relation to current up-to-date diagnostic criteria (Appendix 1); after review we categorized all patients into four groups (Groups A-D; Table 1 ) as shown in Table 1 and described in Appendix 1. We considered a patient to have an LP tumor if the person was categorized to belong to Groups A-C. For CLL patients, absence or presence of splenomegaly was registered as a surrogate marker for early versus more advanced disease.
Approval was obtained from the Swedish National Ethics review board for these studies 
Statistical analysis
For each LP case, the diagnosis from pathology reports in medical records or from the cancer registry was reviewed and a level of diagnostic accuracy was assigned. We calculated the percent of the total LP cases in each category according to the level of diagnostic accuracy by dividing the number of cases in each category by the total number designated as LP cases. This was performed separately for the hospital ascertained and the registry ascertained cases. Further, we estimated the completeness of LP tumor cases reported to and listed in the Swedish Cancer registry. We ascertained the fraction of LP tumor cases in the hospital-based study population that were appropriately recorded to the Swedish Cancer registry. Finally, we estimated the proportion of LP tumor cases with a delayed reporting (3 months or more after diagnosis) to the registry. Chi-square and Fisher exact tests were used for contingency tables.
RESULTS
Altogether, 591 and 595 patients with reported LP tumors were included in the registrybased and the hospital-based study populations, respectively. Patient records could be found and obtained for 494 (83.6%) and 503 (84.5%) of the patients. Close to two thirds (64.9%) of missing records were from the first calendar period (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) .
Diagnostic accuracy of lymphoproliferative tumors

Registry-based study population
The overall proportion of cases that were correctly registered as having an LP tumor diagnosis (Groups A, B, and C) was 98.0 % (484/494) ( were revised to NHL of the following subtypes: reticulum cell sarcoma (n=1), immunoblastic lymphoma (n=1), and diffuse large B-cell lymphoma (n=1).
Among the ten cases without support for a LP tumor diagnosis, four cases were due to coding errors by the Swedish Cancer registry since there was a correct non-LP tumor diagnosis in the medical record; however, six cases were incorrectly diagnosed and reported as LP tumors when the correct diagnosis was other type of malignancies (myelodysplastic syndrome or anaplastic gastric cancer) or benign conditions (folliculitis, actinic reticuloid, reactive plasmocytosis and benign lymphocytosis).
The proportion of LP tumor cases that were both correctly diagnosed and classified (Table 3) .
Hospital-based study population
A total of 492/503 (97.8%) LP tumors were found to be correctly diagnosed (Groups A, B, and C) ( We revised the diagnosis to another type of LP tumor in the following number of cases:
five CLL cases were reclassified to well differentiated lymphocytic lymphoma (n=3), immunocytoma (n=1), and centrocytic lymphoma (n=1); six MM cases were revised to solitary plasmocytoma (n=3), MGUS (n=2) and HL (n= 1, coding error with correct diagnosis in hospital record); one NHL case was reclassified to CLL, and eight HL cases had their diagnosis revised to NHL (centroblastic/centrocytic (n=2), immunocytoma (n=1), immunoblastic (n=1), poorly differentiated lymphocytic, diffuse (n=1), Burkitt (n=1), lymphoepitheloid T-cell (n=1), and centroblastic (n=1)). The diagnoses of four WM cases were revised to IgM MGUS. Among 11 cases without support for an LP tumor diagnosis, eight cases were incorrectly diagnosed as LP malignancies in the Cancer registry, although post-diagnosis corrections were documented in the patients' records for 6 of these 8 patients.
However, the revised diagnosis in the medical records was apparently not reported to the Swedish Cancer registry. For remaining 3 cases without support for an LP tumor diagnosis, the diagnosis in the patient record was a non-LP tumor diagnosis and the cause was thus purely a reporting error in the registry.
The proportion of LP tumor cases that were both correctly diagnosed and classified (Group A) increased over time, from 84.8% (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) to 92.8% (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) . Conversely, the proportion of cases with an incorrect classification of the LP tumor according to the review (Group B) decreased from 8.3% to 5.9% between the first and last calendar periods (Table 3) .
Completeness of the Swedish Cancer registry
We used the hospital-based study population to assess the completeness of reporting to the Swedish Cancer registry. We found that 441/492 (89.6%) of the patients diagnosed with an LP tumor in any of the six included hospitals were subsequently reported to the registry ( 68.8%; Table 4 ).
The median age at diagnosis among patients reported to the Swedish Cancer registry was 66 years and the proportion of patients diagnosed above the age of 80 years was 8.0%
(35/441). Patients who were not reported to the registry had a median age of 74 years and 25.5% (13/51) were 80 years or older. The overrepresentation of older patients among those who were not reported to the registry did not vary over time (data not shown).
When we assessed the fraction of missing LP tumor cases in the Swedish Cancer registry by hospital category, we found that 9.0% and 10.2% of the patients diagnosed in University and non-University hospitals, respectively, were not recorded in the registry. There was no overall gender difference in reporting; however, the under-ascertainment of CLL and WM was more pronounced among women (Table 4 ). For 93.2% of the patients, the date of diagnosis recorded in the Swedish Cancer registry was delayed less than 3 months compared to the date of diagnosis in the patient record. Thus, the date of reporting the LP case in the Cancer registry was 3 or more months delayed (range 3-75 months) for 6.8% of the cases.
The distribution of LP tumors with a 3 or more months delayed date of diagnosis was as follows: NHL (2/102), HL (2/98), MM (9/102), CLL (6/99), and WM (11/91).
DISCUSSION
In this large population-based study including 997 patients diagnosed with a LP Further, a previous Swedish study found 6 29 , a sub-study indicated that 30% of 4,714 patients with a hematopoietic malignancy were not reported to the registry, and 20% of the hematopoietic tumors were inappropriately classified 30 . A study based on the Finnish Cancer registry (1985) (1986) (1987) (1988) ) based on 68,628 cases found a deficit of 1.4% for cancer in general, but for hematopoietic cancers (n=4,906) the rate was substantially higher (7.9%) 4 . In a population-based study from Tromsö in Norway the underreporting of hematopoietic malignancies was found to be as high as 14% based on 114 cases 31 .
Although the overall diagnostic accuracy and completeness of reporting was high, there was some heterogeneity by type of LP tumor. For MM, both the diagnostic accuracy of individual cases and the completeness of the Swedish Cancer registry were very high in contrast to the study mentioned above Goldin, NE Caporaso, and O Landgren) were involved in the interpretation of the data and made important intellectual contributions to the manuscript. All authors read, gave comments, and approved the final version of the manuscript. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the analyses.
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